Abstract
Apoptosis is an induced and ordered process in which the cell actively participates in bringing about its own death. Dysregulation in either of the apoptotic pathways leads to various diseases including cancer, neurodegenerative disorders and autoimmunity. Bcl-2 (B cell lymphoma 2) proteins such as pro-and anti-apoptotic play a vital role in the mitochondrial pathway of apoptosis which results in cellular commitment to death or cell survival. So, therefore many small molecule antagonists that targets Bcl-2 anti-apoptotic proteins that lead to cellular survival are in their pre-clinical and clinical stages. In this review we focus on the apoptotic players of Bcl-2 group of proteins and their anti-apoptotic inhibitors.
Keywords: Apoptosis, Bcl-2 family, BH-3 Domain, Molecular pathways, Small molecule inhibitors
Current Cancer Therapy Reviews
Title:BCL-2 Family Proteins: The Mitochondrial Apoptotic Key Regulators
Volume: 8 Issue: 2
Author(s): P. Daisy and K. Saipriya
Affiliation:
Keywords: Apoptosis, Bcl-2 family, BH-3 Domain, Molecular pathways, Small molecule inhibitors
Abstract: Apoptosis is an induced and ordered process in which the cell actively participates in bringing about its own death. Dysregulation in either of the apoptotic pathways leads to various diseases including cancer, neurodegenerative disorders and autoimmunity. Bcl-2 (B cell lymphoma 2) proteins such as pro-and anti-apoptotic play a vital role in the mitochondrial pathway of apoptosis which results in cellular commitment to death or cell survival. So, therefore many small molecule antagonists that targets Bcl-2 anti-apoptotic proteins that lead to cellular survival are in their pre-clinical and clinical stages. In this review we focus on the apoptotic players of Bcl-2 group of proteins and their anti-apoptotic inhibitors.
Export Options
About this article
Cite this article as:
Daisy P. and Saipriya K., BCL-2 Family Proteins: The Mitochondrial Apoptotic Key Regulators, Current Cancer Therapy Reviews 2012; 8 (2) . https://dx.doi.org/10.2174/157339412800675414
DOI https://dx.doi.org/10.2174/157339412800675414 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multistage Nanovectors Enhance the Delivery of Free and Encapsulated Drugs
Current Drug Targets Editorial: Overview on microRNAs in Cancer Development and Virus Infection
MicroRNA Electrocatalytic Determination of 6-Mercaptopurine Using Multiwall Carbon Nanotubes Paste Electrode in the Presence of Methyldopa
Current Nanoscience Structure and Function of CW Domain Containing Proteins
Current Protein & Peptide Science Dual Role of S100A8 and S100A9 in Inflammation-Associated Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Progress in the Development of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents The Chemistry and Biology of the Bryostatins: Potential PKC Inhibitors in Clinical Development
Current Medicinal Chemistry DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry Evasion of Ribonuclease Inhibitor as a Determinant of Ribonuclease Cytotoxicity
Current Pharmaceutical Biotechnology Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design Computer-Aided Drug Design of Bioactive Natural Products
Current Topics in Medicinal Chemistry Progress of Biological Agents on Psoriatic Arthritis
Current Pharmaceutical Biotechnology Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/ Refractory Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry The Hereditary Disease Array Group (HDAG) - Microarrays, Models and Mechanisms : A Collaboration Update
Current Genomics Novel Pharmacodynamic Approach to Assess Obatoclax (GX15-070) and Bortezomib (BTZ) Synergism in Non-Hodgkin’s Lymphoma
Clinical Cancer Drugs Troika of the Mouse Blastocyst: Lineage Segregation and Stem Cells
Current Stem Cell Research & Therapy Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Current Pharmaceutical Design Synthetic Peptides in the Diagnosis of HIV Infection
Current Protein & Peptide Science A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents
Current Pharmaceutical Design Recent Advances in Peptide-Based Approaches for Cancer Treatment
Current Medicinal Chemistry